Patrys Completes Reliis Acquisition Adding Injectable Quetiapine to Pipeline

Patrys Limited (ASX: PAB) has finalised the acquisition of Reliis Pty Ltd, with Reliis now operating as a wholly-owned subsidiary. The transaction, originally announced on 26 November 2025, reached completion on 28 January 2026 following shareholder approval at the General Meeting held on 19 January 2026.

The acquisition adds RLS-2201, a proprietary injectable quetiapine formulation, to Patrys’ clinical-stage pipeline. This marks a strategic expansion beyond the company’s core deoxymab antibody platform into a lower-risk, faster-to-market clinical program targeting acute-care settings.

All conditions precedent under the Share Sale Agreement have been satisfied or waived, and all transaction documents have been executed. The company will now focus on advancing RLS-2201 through its next phase of clinical development whilst integrating the program within its broader development platform.

Chair Commentary

“Completing the acquisition of Reliis delivers on our strategy to expand Patrys’ clinical-stage pipeline through the addition of a differentiated and lower-risk program. We believe RLS-2201 has the potential to address a significant unmet need in acute-care settings, and we look forward to progressing the program within Patrys,” said Peter Christie, Non-Executive Chair.

The acquisition represents successful execution of a stated diversification strategy, providing shareholders with exposure to a de-risked asset built on established pharmacology rather than novel drug discovery.

What is RLS-2201 and why does an injectable quetiapine matter?

Quetiapine is an established antipsychotic medication with a well-documented safety profile across multiple approved indications. RLS-2201 represents a proprietary injectable formulation of this proven therapeutic, specifically designed for acute-care environments including intensive care, aged care, and palliative care settings.

The target condition is delirium, a neuropsychiatric syndrome associated with increased morbidity, extended hospital stays, and higher healthcare costs. Critically, there are currently no approved treatments available for delirium, representing a significant unmet clinical need in acute-care environments.

The injectable reformulation approach offers three key advantages over traditional oral administration:

1. Rapid onset for patients unable to take oral medication
2. Predictable dosing in controlled clinical environments
3. Acute-care suitability for intensive care and emergency settings

For investors, the reformulation strategy fundamentally differs from traditional drug development. RLS-2201 leverages quetiapine’s established safety and pharmacology profile rather than discovering new molecular entities. This approach typically offers shorter development timelines, reduced regulatory risk, and clearer pathways to commercialisation compared to novel drug candidates.

The clinical-stage status means RLS-2201 has already demonstrated sufficient promise to warrant continued development, whilst the reformulation approach suggests a fundamentally different risk-return profile than early-stage discovery programs.

Two new directors bring clinical trials and capital markets expertise to the board

The completion of the acquisition includes the appointment of two Non-Executive Directors to the board, effective immediately. Both appointments were part of the acquisition terms and bring complementary expertise aligned with advancing RLS-2201 through clinical development.

Kite brings over 20 years of experience across biotech, resources, and energy sectors. Her qualifications include Chartered Accountant status, Fellowship of the Governance Institute of Australia, and a Graduate Diploma in Investor Relations. She currently chairs both the Finance and Investment Committee and the Remuneration and Nominations Committee at Mosaic Community Care, whilst also serving on the Australasian Investor Relations Association Small Cap Council Committee.

Cercarelli contributes over two decades of healthcare and clinical research operations expertise. He holds an MBA and postgraduate qualifications in Business and Health Services Management. As Chief Operating Officer of the Australian Clinical Trials Alliance (ACTA), the national peak body for clinical trials, he provides direct insight into trial execution frameworks. He also serves on the CT.IQ Executive and Steering Committees and the PARTNER Network Advisory Group.

The dual appointments strengthen Patrys’ capability in two critical areas. Kite adds capital markets sophistication and governance depth at a stage where investor communication around clinical milestones becomes increasingly important. Cercarelli enhances clinical development oversight as RLS-2201 progresses through its next phase, bringing operational expertise in trial design and execution.

Consideration securities to be issued

With the acquisition finalised, Patrys will proceed with the issuance of consideration securities as approved by shareholders. The securities comprise four categories:

• Fully paid ordinary shares
• Performance rights
• Convertible note shares
• Facilitation shares

Full details of the consideration structure and terms were outlined in the company’s announcement dated 26 November 2025. Shareholders should anticipate these securities appearing in the company’s registry following standard issuance procedures.

What comes next for Patrys and RLS-2201

The acquisition completion marks the beginning of the next development phase rather than a conclusion. Management has indicated the company will focus on advancing RLS-2201 through its next clinical milestone whilst integrating the program within Patrys’ existing development platform.

The clinical-stage designation means RLS-2201 has already progressed beyond preclinical validation, positioning it closer to potential commercialisation than early-stage candidates. The integration into Patrys’ infrastructure provides access to established clinical development capabilities and potential operational efficiencies.

This acquisition complements rather than replaces the company’s existing deoxymab antibody pipeline. Patrys now operates a dual-platform strategy: the original cell-penetrating antibody technology targeting multiple indications, and the newly acquired reformulation program targeting acute-care delirium management.

For investors, the near-term catalyst sequence will likely centre on RLS-2201 development milestones, including trial design announcements, patient enrolment updates, and interim or final data readouts. The reformulation approach suggests these milestones may materialise on shorter timelines than traditional drug development programs, though execution risk remains present in any clinical-stage asset.

The acquisition demonstrates capital allocation towards clinical assets with established proof-of-concept and clearer regulatory pathways. Whether this strategy delivers superior risk-adjusted returns will depend on RLS-2201’s clinical performance and the company’s ability to execute development activities efficiently within budget constraints.

Want more Biotech breaking news and analysis?

Patrys’ acquisition of Reliis represents the type of strategic development that can materially impact biotech portfolios. RLS-2201’s progression through clinical milestones, combined with the dual-platform strategy now in place, creates a series of potential catalysts that active investors monitor closely. The reformulation approach and acute-care focus differentiate this asset within the ASX biotech landscape.

Investors tracking the biotech sector can access breaking news and comprehensive analysis through the Big News Blast, a free email service trusted by 20,000+ subscribers. The service delivers immediate alerts on ASX developments across biotech, technology, healthcare, finance, and industrial sectors—excluding resources. To receive these free alerts covering the next significant biotech announcement, click the “Free Alerts” button in the menu at StockWire X.